Corcept’s Nenocorilant Combo Study Moves Forward, Expanding Its Oncology Ambitions

Corcept Therapeutics (CORT) announced an update on their ongoing clinical study.

Study Overview
This study, officially titled “A Phase 1b/2, Open-Label, Dose-Finding and Proof of Concept Study of Nenocorilant in Combination With Anti-Programmed Cell Death/(Ligand) 1 in Patients With Advanced Solid Malignancies,” aims to test Corcept Therapeutics’ drug nenocorilant together with an existing cancer immunotherapy in patients with late-stage solid tumors. The main goals are to find a safe dose range, check basic safety and tolerability, and look for early signs that the drug combo may help control cancer growth, which could support future, larger trials and broaden Corcept’s oncology pipeline.

Intervention/Treatment
The study tests nenocorilant, an oral tablet, at three daily dose levels (200 mg, 300 mg, and 400 mg) in combination with nivolumab, an intravenous immune checkpoint inhibitor already used in many cancers. Nenocorilant is being developed to potentially boost or modify the immune response, while nivolumab is designed to help the immune system better attack cancer cells. Together, the combination is meant to improve treatment outcomes in patients with advanced solid tumors that are hard to treat.

Study Design
This is an interventional Phase 1b/2 trial using a dose-finding, proof-of-concept approach. Patients are assigned in a non-randomized, stepwise (sequential) manner to one of three experimental cohorts based on nenocorilant dose, all combined with nivolumab. The trial is open-label, meaning both doctors and patients know what treatment is given, and there is no placebo or blinded control arm. The primary focus is treatment: identifying the maximum tolerated or optimal dose and gathering early signals on how well the combination works.

Study Timeline
The study was first submitted to the registry on December 1, 2025, marking the formal start of its public record and signaling that site activation and enrollment planning are underway. The most recent update was submitted on January 26, 2026, confirming the status as “recruiting,” which indicates active enrollment of patients. Primary completion and final completion dates are not yet clearly posted, but investors should assume that key initial safety and dosing data will likely emerge first, followed later by early efficacy readouts, which will be important catalysts for the stock as milestones are reached.

Market Implications
For Corcept Therapeutics (CORT), this study signals a strategic push beyond its legacy endocrine focus into oncology, a much larger addressable market. Positive safety and early efficacy signals from this trial could support a re-rating of Corcept’s pipeline value, diversify revenue expectations, and reduce perceived dependence on its current commercial portfolio. The partnership with nivolumab, a leading checkpoint inhibitor in the Bristol Myers Squibb portfolio, also aligns Corcept with a well-established immuno-oncology class, which may be viewed favorably by investors if the combination can differentiate on outcomes or safety. However, the immuno-oncology space is crowded, with multiple large-cap players (e.g., Merck’s Keytruda, BMS’s Opdivo) and numerous combination studies; investors should temper expectations until clear clinical advantages emerge, as early-stage oncology assets carry high binary risk and long timelines. Near term, the recruiting status and recent update mainly strengthen the story that Corcept is executing on its pipeline, which may support sentiment but is unlikely to drive a major revaluation until data are released.

The study is currently ongoing and recently updated, with further details available on the ClinicalTrials.gov portal under identifier NCT07276373.

To learn more about CORT’s potential, visit the Corcept Therapeutics drug pipeline page.